• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Molecular Partners AG - American Depositary Shares (NQ:MOLN)

3.609 -0.111 (-2.98%)
Delayed Quote Updated: 10:34 AM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,448
Open 3.560
Bid (Size) 3.650 (2,700)
Ask (Size) 3.820 (500)
Prev. Close 3.720
Today's Range 3.550 - 3.610
52wk Range 3.530 - 5.360
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70
Today 1:00 EDT
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
August 25, 2026
From Molecular Partners
Via GlobeNewswire

Performance

52-Week Range 32.7% below 52-week high
3.609
3.5352W Low 5.3652W High
1 Week 5.0% below 1-week high
3.561W Low 3.801W High

Molecular Partners AG - American Depositary Shares (MOLN) traded between $3.53 and $5.36 over the past 52 weeks and last traded at $3.61, 32.7% below its 52-week high. Over the past week it ranged between $3.56 and $3.80.

Past 12 Months
+1.4%
-9.5%
-9.1%
-16.8%
-14.5%
-2.5%
1W +$0.05
1M -$0.38
3M -$0.36
6M -$0.73
YTD -$0.61
1Y -$0.09

MOLN was -2.5% over the past year, -16.8% over six months, -14.5% year to date, +1.4% in the last week.

12 Months vs Market
MOLN
-2.5%
DIA
+12.2%
SPY
+13.5%
QQQ
+15.0%
IWM
+11.7%

Over the past 12 months MOLN returned -2.5% versus DIA (Dow) +12.2%, SPY (S&P 500) +13.5%, QQQ (Nasdaq 100) +15.0% and IWM (Russell 2000) +11.7%.

Volume & Liquidity 2.28× 3-mo avg
Today 3,448 3-mo avg 1.5K
1W
1.8K
1M
1.9K
3M
1.5K
6M
4.3K
YTD
4.3K
1Y
4.8K

MOLN most recently traded 3,448 shares against a 3-month average daily volume of 1.5K.

More News

Read More
News headline image
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
July 16, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
July 15, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
July 06, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
July 02, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
May 30, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
May 26, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
May 12, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
May 04, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
May 01, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
April 19, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
April 14, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
March 23, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes
March 19, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Hold Three Poster Presentations at AACR 2026
March 17, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Reports Highlights and Financial Results for Full Year 2025
March 12, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
February 26, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
February 26, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
February 02, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
January 11, 2026
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
December 11, 2025
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
December 07, 2025
From Molecular Partners
Via GlobeNewswire
News headline image
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
November 12, 2025
From Molecular Partners
Via GlobeNewswire

Frequently Asked Questions

Is Molecular Partners AG - American Depositary Shares publicly traded?
Yes, Molecular Partners AG - American Depositary Shares is publicly traded.
What exchange does Molecular Partners AG - American Depositary Shares trade on?
Molecular Partners AG - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Molecular Partners AG - American Depositary Shares?
The ticker symbol for Molecular Partners AG - American Depositary Shares is MOLN on the Nasdaq Stock Market
What is the current price of Molecular Partners AG - American Depositary Shares?
The current price of Molecular Partners AG - American Depositary Shares is 3.609
When was Molecular Partners AG - American Depositary Shares last traded?
The last trade of Molecular Partners AG - American Depositary Shares was at 10/22/26 10:34 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap